USE OF THE ADDICTION RESEARCH CENTER INVENTORY
(SEDATION SUBSCALE) AND THE KAROLINSKA SLEEPINESS SCALE TO EVALUATE SUBJECTIVE ALERTNESS AFTER SINGLE ORAL DOSES OF ZALEPLON
IN THREE NOVEL RELEASE FORMULATIONS
Nathalie Pross, Luc Staner, Rémy Luthringer, Corinne Staner
Forenap Pharma, Rouffach, France
PHARMACODYNAMIC PROFILE OF THREE NOVEL RELEASE FORMULATIONS
OF ZALEPLON VERSUS PLACEBO AND MARKETED ZALEPLON MEASURED BY ELECTROENCEPHALOGRAPHY AND THE
KAROLINSKA DROWSINESS TEST IN HEALTHY VOLUNTEERS
Sarah Otmani, Laurent Soufflet, Luc Staner, Rémy Luthringer
Forenap Pharma, Rouffach, France
PHARMACODYNAMIC PROFILE OF THREE NOVEL RELEASE FORMULATIONS
OF ZALEPLON IN NORMAL VOLUNTEERS AS EVALUATED BY THE MULTIPLE SLEEP LATENCY TEST
James Walsh1, Corinne Staner2, Anne Tisserant2, Rémy Luthringer2, Luc Staner2
1. St Luke’s Hospital, Chesterfield, MO, USA; 2. Forenap Pharma, Rouffach, France
PHARMACOKINETIC PROFILE OF SINGLE ORAL DOSES OF ZALEPLON IN
THREE NOVEL FORMULATIONS IN NORMAL VOLUNTEERS
Michael Gassen1, Anita Kress1, Jean-François Nedelec2, Céline Francart2, Corinne Staner2.
1. Harlan Laboratories, Itingen, Switzerland; 2. Forenap Pharma, Rouffach, France
RELATIONSHIP OF SUBJECTIVE AND OBJECTIVE ENDPOINTS FOR OUTCOMES
OF A PHASE I TRIAL OF A POTENTIAL NEW SLEEP AGENT
Rémy Luthringer, Nathalie Pross, Sarah Otmani, Corinne Staner
Forenap Pharma, Rouffach, France
|
|
|
